Salute e Benessere

138th Canton Fair Showcases Resilience of China's Craft Ceramics and Glassware…

In the Art Ceramics section, another veteran exhibitor is advancing intelligent manufacturing to future-proof its production. The company has been adopting technologies such as 3D printing and digital glazing robots while refining mid-temperature glaze techniques that lower energy consumption and increase material recyclability. These innovations underscore a thoughtful balance between technological progress and environmental responsibility. In the Art Ceramics section, another veteran...
PR Newswire
26/10/2025

Novartis showcases significant immunology advancements in ACR congress with new…

Late-breaking positive Phase III data from ianalumab NEPTUNUS-1 and NEPTUNUS-2 trials in Sjögren’s disease to be presented Biomarker data informing use of investigational CAR-T cell therapy rapcabtagene autoleucel (YTB323) in systemic lupus erythematosus also to be presentedData underscore Novartis commitment to advance innovative medicines for complex, difficult-to-treat autoimmune diseases with high unmet needNovartis to hold virtual investor event following ACR...
Nasdaq GlobeNewswire
25/10/2025

Renowned Indian Entrepreneur Deepinder Goyal Launches 'Continue Research' with a…

Continue Research was founded two years ago as an independent scientific initiative exploring upstream biological mechanisms — the fundamental leverage points where small interventions could meaningfully transform how humans age and live. The team has been investigating a core hypothesis on human aging that, if validated, could significantly reshape current biological understanding. Continue Research was founded two years ago as an independent scientific initiative exploring upstream...
PR Newswire
25/10/2025

Cardiovalve Completes TARGET Study Enrollment for CE Registration Study for…

With enrollment now complete, the company is preparing to submit its CE Mark application to European regulators later this year. Pending approval, commercial launch of the Cardiovalve TR system in Europe is projected for 2027. With enrollment now complete, the company is preparing to submit itsCE Mark applicationto European regulators later this year. Pending approval,commercial launch of the Cardiovalve TR system inEuropeis projected for 2027. Building on this achievement,...
PR Newswire
25/10/2025

Innocan Pharma to Present at the 2025 ThinkEquity Conference

Innocan's presenters will include Iris Bincovich, CEO, Roni Kamhi, COO and Innocan's distinguished advisory board member Dr. Joseph V. Pergolizzi, Jr., M.D, an expert in internal, perioperative and pain medicine, critical and palliative care, pharmacology, drug development and regulatory affairs. Innocan's presenters will include Iris Bincovich, CEO,Roni Kamhi, COO and Innocan's distinguished advisory board member Dr. Joseph V. Pergolizzi, Jr., M.D, an expert in internal, perioperative and...
PR Newswire
24/10/2025

CARBIOS announces the publication of its Interim report for the first half of…

Clermont-Ferrand (France), October 24, 2025 (08:00 pm CEST). CARBIOS (Euronext Growth Paris: ALCRB), a pioneer in the development and industrialization of biological technologies to reinvent the life cycle of plastics and textiles, informs its shareholders and the financial community that it has made available its Interim report for the first half of 2025. This 2025 Interim report is available in English and can be downloaded from:The Company's website atwww.carbios.comunder the...
Nasdaq GlobeNewswire
24/10/2025

Northwest Biotherapeutics Announces That Its Acquisition of Advent BioServices…

As previously announced, through the acquisition of Advent, NWBio is receiving all of Advent's fixed assets, including extensive cryostorage and other equipment purchased by Advent over the last several years. Intellectual property and other intangibles that Advent had acquired are also included. As previously announced, through the acquisition of Advent, NWBio is receiving all of Advent's fixed assets, including extensive cryostorage and other equipment purchased by Advent over the last several…
PR Newswire
24/10/2025

Fagron’s share buy-back program: Weekly update

Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 24 October 2025 – 6PM CET Fagron’s share buy-back program: Weekly update In the period from 20 October 2025 through 24 October 2025, Fagron purchased 45,000 of its owns shares at an average price of €21.0115 per share corresponding to a total amount of €945,517.50. These purchases are part of the share buy-back program of up to 200,000 Fagron shares to fulfill Fagron’s obligations under its long-term incentive scheme,...
Nasdaq GlobeNewswire
24/10/2025

Dental tourism enters the winter season in Turkey; Antlara Dental launches…

Advantages of the winter season: Winter visitors benefit from cheaper airfare and lodging costs as well as a more tranquil treatment experience. In addition, dental offices offer seasonal deals that make procedures even cheaper. Along with the financial benefits, the winter air makes it more comfortable for treatment, and wounds that were difficult to heal after treatment because of high temperatures no longer exist. Meanwhile, dental labs see a decrease in business during...
PR Newswire
24/10/2025

First Characterization of a TDP-43 PET Tracer Published in Nature Communications…

First Characterization of a TDP-43 PET Tracer Published inNature CommunicationsShowing Potential of AC Immune’s ACI-19626 in Precision Medicine Aggregated TDP-43 is a pathological hallmark of neurodegenerative diseases including ALS, FTD and LATE, and a co-pathology in Alzheimer’s and Parkinson’s diseasesPET imaging of aggregated TDP-43 could facilitate precision medicine in these diseases, whose shared clinical features complicate differential diagnosis, potentially delaying...
Nasdaq GlobeNewswire
24/10/2025

Biogen Licenses Oral C5aR1 Antagonist from Vanqua Bio to Expand Immunology…

The oral C5aR1 antagonist is designed to modulate neutrophil-driven inflammation, a central mechanism underlying many inflammatory diseasesCAMBRIDGE, Mass. and CHICAGO, Oct.24, 2025(GLOBE NEWSWIRE) -- BiogenInc. (Nasdaq: BIIB) and Vanqua Bio today announced a license agreement granting Biogen exclusive worldwide rights to Vanqua’s preclinical, oral C5aR1 antagonist. This agreement strengthens Biogen’s immunology strategy by advancing a proven immune mechanism with the potential to...
Nasdaq GlobeNewswire
24/10/2025

Sobi showcases new data across rare inflammatory conditions at ACR 2025

Summary of full Sobi data to be presented at ACR 2025: Summary of full Sobi data to be presented at ACR 2025: Date: Tuesday 28 October Session time: 1:00 PM - 2:30 PM CT Presentation time: 1:30 PM - 1:45 PM CT Date: Tuesday 28 October Session time: 1:00 PM - 2:30 PM CT Presentation time: 1:45 PM - 2:00 PM CT Date: Monday 27 October Presentation time: 10:30 AM - 12:30 PM CT Date: Tuesday 28 October Presentation time: 10:30 AM - 12:30 PM CT ...
PR Newswire
24/10/2025

The Future of Life Sciences, Omics and AI Examined by Leading Global Genomic…

Discussions will span global collaboration in omics and AI, cancer genomics, biodiversity and multi-omics of deep-sea organisms, metagenomics and epidemiology, public health and precision medicine, and the transformative potential of AI in healthcare and across life sciences. Discussions will span global collaboration in omics and AI, cancer genomics, biodiversity and multi-omics of deep-sea organisms, metagenomics and epidemiology, public health and precision medicine, and the transformative...
PR Newswire
24/10/2025

Ribo Granted EMA Orphan Drug Designation for siRNA Therapeutic RBD1016 for…

About Hepatitis D Virus (HDV)HDV is the most severe form of viral hepatitis and occurs only in individuals co-infected with hepatitis B virus (HBV). HDV accelerates liver disease progression, significantly increasing the risk of cirrhosis, liver failure, and hepatocellular carcinoma. It is estimated that 12–20 million people globally are affected by HDV, with limited therapeutic options currently available. About Hepatitis D Virus (HDV)HDV is the most severe form of viral hepatitis and...
PR Newswire
24/10/2025

Smartee Strengthens European Presence with New UK Subsidiary and Orthodontic…

Leveraging 21 years of expertise in clear aligner technology, the Smartee UK team will collaborate with local dental institutions, hospitals, and academic organizations to advance research, clinical training, and innovation. The center also aims to develop region-specific orthodontic solutions and organize professional education programs to support practitioners throughout Europe. Leveraging 21 years of expertise in clear aligner technology, the Smartee UK team will collaborate with local...
PR Newswire
24/10/2025

Vistin Pharma ASA: Invitation to Q3 2025 conference call

Vistin Pharma ASA (VISTN) will release its third quarter and YTD 2025 results on Friday 31st of October 2025. Vistin Pharma will host a conference call for all shareholders and interested parties on the same day at 08:30 CET. There will be a Q&A session following the management discussion.The conference call will be held in English.The third quarter conference call will be available via web and audio through the following access points: Webcast:https://edge.media-server...
Nasdaq GlobeNewswire
24/10/2025

Polpharma Group Announces Leadership Transition – Sebastian Szymanek appointed…

Polpharma Group, one of the largest pharmaceutical groups operating across Central and Eastern Europe and Central Asia, announces a planned leadership transition. EffectiveJanuary 1, 2026,Markus Sieger will step down as CEO of the Group, after a decade of dedicated service. He will continue to support the strategic development of the Group as a member of theSupervisory Board, in line with the succession plan agreed upon at the start of his tenure.Under Markus Sieger’s...
Nasdaq GlobeNewswire
24/10/2025

Avextra Supports Phase II Clinical Trial in Italy on Cannabis-based medicines…

First patient enrolled in randomized, placebo-controlled studyBensheim, 24. October 2025– Neurodegenerative diseases represent one of the biggest challenges of our time. In Germany alone, there are currently around 1.8 million people living with dementia, a figure that is set to rise to 2.7 million by 2050. Increased life expectancy, combined with the growing number of patients, is having an increasingly significant impact on those affected, their families, and national healthcare...
Nasdaq GlobeNewswire
24/10/2025

49,164 Orion Corporation A shares converted into B shares

ORION CORPORATIONSTOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE24 OCTOBER 2025 at 9.00 EEST 49,164 Orion Corporation A shares converted into B shares In accordance with Section 3 of the Articles of Association of Orion Corporation, 49,164 A shares have been converted into 49,164 B shares. The conversion has been entered into the Trade Register on 24 October 2025.The total number of shares in Orion Corporation is 141,134,278...
Nasdaq GlobeNewswire
24/10/2025

NANOBIOTIX Announces Updates to JNJ-1900 (NBTXR3) Clinical Program Following…

PARIS and CAMBRIDGE, Mass., Oct.24, 2025(GLOBE NEWSWIRE) --NANOBIOTIX(Euronext: NANO –– NASDAQ: NBTX – the ‘‘ Company ’’), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced updates to the JNJ-1900 (NBTXR3) clinical development program.Nanobiotix has completed the transfer of NANORAY-312 sponsorship, initiated in 3Q2024, in the majority of regions along...
Nasdaq GlobeNewswire
24/10/2025

ONWARD Medical Successfully Raises Over EUR 50 Million in Capital Increase

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THE PRESS RELEASE.THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE (7)(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014)Successful transaction supported by strong demand from existing...
Nasdaq GlobeNewswire
24/10/2025

Press release: Q3: continued sales and earnings progress

Q3: continued sales and earnings progressParis, October 24, 2025Q3 sales growth of 7.0% at CER 1and business earnings per share (EPS) 2of €2.91Pharma launches increased sales by 57.1%, reaching €1.0 billion, driven by ALTUVIIIO and AyvakitDupixent sales increased by 26.2% to €4.2 billion, first time above €4 billion in a quarterVaccines sales decreased by 7.8% to €3.4 billion, from lower influenza salesResearch and Development expenses were €1.8 billion, an...
Nasdaq GlobeNewswire
24/10/2025

Purpose Brands Announces Grand Opening of First Anytime Fitness Club in Dubai…

"We are thrilled to bring the Anytime Fitness brand to UAE and officially open the first club's doors in Dubai," said Faheem Essop, CEO, Purple Fitness. "Every detail, including the full suite of world-class Technogym fitness equipment and the SmartCoaching ecosystem via the AF App, has been built to meet the global standards set by this world-class fitness brand. We are here to deliver accessible, personalized coaching, nutrition and recovery services for the people of…
PR Newswire
24/10/2025

Mismatch Repair Deficiency Market Forecasts Strong Expansion During the Forecast…

Mismatch Repair Deficiency Market Summary Mismatch Repair Deficiency Market Summary Discover the mismatch repair deficiency new treatment @New Treatments for Mismatch Repair Deficiency Key Factors Driving the Growth of the Mismatch Repair Deficiency Market Rising Prevalence of dMMR-Associated Cancers Mismatch repair deficiency is a hallmark of various cancers, including colorectal, endometrial, and gastric cancers. The increasing incidence of these cancers has...
PR Newswire
23/10/2025
Altri  Comunicati